We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
+$34.2M
Cap. Flow %
1.92%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.24%
2 Healthcare 10.61%
3 Energy 0.15%
4 Communication Services 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARNA
126
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.36M 0.08%
+21,570
New +$1.43M
CGEN icon
127
CALL
Compugen
CGEN
$234M
$1.35M 0.08%
+1,287
New +$14.2K
FURX
128
CALL
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$1.32M 0.07%
+152
New +$11.7K
STAB
129
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
$1.24M 0.07%
+91,308
New +$1.49M
CBST
130
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$1.21M 0.07%
+16,590
New +$1.24M
NVAX icon
131
Novavax
NVAX
$1.58B
$1.14M 0.06%
12,575
+11,075
+738% +$1.24M
GEVA
132
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.12M 0.06%
+13,538
New +$1.25M
INVA icon
133
Innoviva
INVA
$1.49B
$1.07M 0.06%
+42,853
New +$1.25M
AMPE
134
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$1.06M 0.06%
6
+5
+500% +$11.8K
MNKD icon
135
CALL
MannKind Corp
MNKD
$1.21B
$1.02M 0.06%
507
-5,611
-92% -$160K
ABUS icon
136
CALL
Arbutus Biopharma
ABUS
$1.01B
$967K 0.05%
+450
New +$8.09K
MDGN.WS
137
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
$940K 0.05%
+817,050
New +$2.68M
PLUR icon
138
Pluri
PLUR
$14.6M
$938K 0.05%
+3,167
New +$1.02M
EXAS
139
PUT
DELISTED
Exact Sciences
EXAS
$928K 0.05%
655
-740
-53% -$9.99K
ALXA
140
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$904K 0.05%
2,040
– –
THMO
141
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$900K 0.05%
+59
New +$1.03M
OREX
142
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$896K 0.05%
138
+126
+1,050% +$8.52K
BMY icon
143
PUT
Bristol-Myers Squibb
BMY
$131B
$894K 0.05%
172
-60
-26% -$3.19K
PRTA icon
144
CALL
Prothena Corp
PRTA
$458M
$862K 0.05%
+225
New +$7.25K
XOMA
145
DELISTED
Xoma
XOMA
$858K 0.05%
8,236
-12,434
-60% -$1.81M
AVEO
146
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$857K 0.05%
57,342
-91,670
-62% -$1.65M
SRPT icon
147
CALL
Sarepta Therapeutics
SRPT
$2.16B
$843K 0.05%
351
-1,756
-83% -$44.8K
ATHE
148
CALL
Alterity Therapeutics
ATHE
$73.7M
$838K 0.05%
50
+42
+525% +$23.2K
ALIM
149
PUT
DELISTED
Alimera Sciences
ALIM
$820K 0.05%
+69
New +$6.7K
ACAD icon
150
PUT
Acadia Pharmaceuticals
ACAD
$4.74B
$810K 0.05%
333
-236
-41% -$5.97K
4 5
6
7 8

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management's Q1 2014 filing shows 107 new, 59 increased, 54 reduced and 92 closed positions. Its largest new stake was Tenax Therapeutics: 66 shares worth $11.8M. The largest sale was MannKind Corp, an estimated $22.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Energy.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.